AstraZeneca is investing $245 million in biotech company CELLECTIS.

AstraZeneca is investing $245 million in biotech company CELLECTIS.

Together with the French biotech company CELLECTIS, the British pharmaceutical company AstraZeneca plans to develop next-generation therapeutics in the areas of oncology, immunology and rare diseases. AstraZeneca wants to invest $245 million in this. An initial payment of $105 million will be made in the fourth quarter of this year, consisting of $80 million in equity for a 22 percent stake in CELLECTIS and $25 million in cash. An additional $140 million in equity investment is planned once regulatory and other approvals are received. This is scheduled to be completed at the beginning of 2024 and increase the total stake in CELLECTIS to 44 percent. AstraZeneca intends to use CELLECTIS' gene editing technologies and manufacturing capabilities to develop new cell and gene therapy products.

According to the article, CELLECTIS shares rose by 152.22 percent to 2.27 euros on EURONEXT in Paris. AstraZeneca shares were temporarily 1.29 percent firmer in London at 103.82 pounds.

According to a report from www.finanzen.net, CELLECTIS shares are in focus due to AstraZeneca's investment. Through the collaboration, AstraZeneca will gain access to CELLECTIS' innovative technologies, thereby strengthening its position in the field of gene editing and gene therapy. This could have a long-term impact on the market and drive growth in oncology, immunology and rare diseases. The investment is a sign of AstraZeneca's confidence in the future of biotechnology and the importance of innovative therapeutic approaches. It remains to be seen how the collaboration will develop and what new products and therapies will emerge from it.
Source: According to a report by www.finanzen.net